Clinical trials: Patients With Thyroid Cancer
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Thyroid Cancer
Thyroid Cancer and (FDG)PET/CT Scan
Background and Rational (Introduction) Differentiated thyroid carcinoma (DTC) have favorable prognosis. Overall 10-year survival is 93% for papillary carcinoma, and 85% for follicular carcinoma(1).
- Trial name
- NCT04128631
- Volunteers
- 35 people
- Sponsor
- Assiut University
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Thyroid Cancer, Lymph Node Metastases
Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid
Papillary thyroid microcarcinoma (PTMC), defined as a tumor with larger diameter ≤ 1 cm, is considered a tumor with an indolent course and an excellent prognosis.
- Trial name
- NCT04274829
- Testing
- Thyroidecomt and lymphectomy
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Cagliari
Recurrent Malignant Solid Neoplasm, Recurrent Melanoma
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment.
- Conditions
- Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Thyroid Gland Carcinoma
- Trial name
- NCT01709435
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 23 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Brain Neoplasms, Lung Neoplasms
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
Positron Emission Tomography (PET) is a specialised nuclear medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity.
- Conditions
- Brain Neoplasms, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms
- Trial name
- NCT00123760
- Testing
- Positron Emission Tomography (PET) scan
- Where
- Canada
- Volunteers
- 10,838 people
- Sponsor
- AHS Cancer Control Alberta
Thyroid Cancer, Recurrence
Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma
Several studies have indicated that [124I]-PET/CT or [18F]-FDG-PET/CT may be useful to locate recurrent differentiated thyroid carcinoma lesions in patients with elevated thyroglobulin levels but who do not show pathological…
- Trial name
- NCT01374659
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Korean Association of Endocrine Surgeons
Thyroid Neoplasms, Carcinoma
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this.
- Conditions
- Thyroid Neoplasms, Carcinoma, Thyroid Cancer, Metastatic Cancer
- Trial name
- NCT00804830
- Testing
- Bevacizumab
- Where
- 3 sites in Sweden
- Volunteers
- 15 people
- Sponsor
- Region Skane
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue…
- Trial name
- NCT04204928
- Testing
- pralsetinib (BLU-667)
- Sponsor
- Blueprint Medicines Corporation
Head and Neck Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004089
- Testing
- filgrastim, fluorouracil, hydroxyurea
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Cancer
The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
The aim of this study is to evaluate the prognostic value of postoperative99mTc-pertechnetate scanning in patients with DTC.
- Trial name
- NCT04563780
- Testing
- 99mTC pertechnetate thyroid scan
- Where
- Egypt
- Volunteers
- 113 people
- Sponsor
- Assiut University
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by…
- Conditions
- Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Trial name
- NCT03093909
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine.
- Trial name
- NCT00004062
- Testing
- azacitidine, liothyronine sodium, iodine I 131
- Where
- United States
- Sponsor
- Lucille P. Markey Cancer Center at University of Kentucky
Ovarian Insufficiency, Radiation Exposure
Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer
Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated.
- Trial name
- NCT04396158
- Testing
- radioactive iodine
- Volunteers
- 38 people
- Sponsor
- Assiut University
Thyroid Cancer
Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
Single intravenous administration of TAH-1005 is performed in patients with differentiated thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect with standard treatment or who have difficulty…
- Trial name
- NCT05275946
- Testing
- Targeted alpha therapy
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Osaka University
Medullary Thyroid Cancer
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that…
- Trial name
- LIBRETTO-531 (NCT04211337)
- Testing
- Selpercatinib, Cabozantinib, Vandetanib
- Where
- 143 sites in United States, Australia and 18 more
- Volunteers
- 291 people
- Sponsor
- Loxo Oncology, Inc.
Papillary Thyroid Cancer
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
The incidence of papillary thyroid cancer (PTC) has been on the rise in recent years, and 20%-50% of PTC patients will have lymph node metastasis.
- Trial name
- NCT06286631
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Thyroid Cancer
Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.
1. Determine the frequency of utilizing single and multiple doses of radioactive iodine (RAI) in treatment of differentiated thyroid cancer. 2.
- Trial name
- NCT06134830
- Testing
- RAI
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hypocalcemia
Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection
the increased risk of hypocalcemia following total thyroidectomy plus central neck dissection can be minimized by routine administration of oral calcium and vitamin D supplements during the early postoperative period.
- Trial name
- NCT00630214
- Testing
- Oral calcium plus vitamin D, Oral calcium alone
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Asan Medical Center